Related Experiment Video
Updated: Aug 15, 2025

12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.5K
Morphological differences between the two major subtypes of multiple system atrophy with cognitive impairment
1Institute of Clinical Neurobiology, Alberichgasse 5/13, A-1150, Vienna, Austria.
Parkinsonism & Related Disorders
|January 5, 2023
Summary
Neuropathology differs between multiple system atrophy parkinsonism-predominant (MSA-P) and cerebellar ataxia-predominant (MSA-C) forms. MSA-P shows higher tau pathology, while MSA-C exhibits greater amyloid pathology, impacting cognitive decline.
Area of Science:
- Neuropathology
- Neurodegenerative Diseases
- Multiple System Atrophy
Background:
- Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with two main phenotypes: parkinsonism-predominant (MSA-P) and cerebellar ataxia-predominant (MSA-C).
- Cognitive impairment is a recognized feature in MSA, but its neuropathological underpinnings, particularly in relation to distinct phenotypes and co-existing pathologies, require further elucidation.
Purpose of the Study:
- To compare the neuropathological features of alpha-synuclein and Alzheimer pathologies between MSA-P and MSA-C.
- To investigate the association between neuropathological findings and cognitive impairment in different MSA phenotypes.
Main Methods:
- Neuropathological examination of 35 MSA-P and 15 MSA-C cases.
- Semiquantitative evaluation of alpha-synuclein, tau, amyloid-beta (Aβ) load, cerebral amyloid angiopathy (CAA), and Lewy co-pathology.
- Correlation of neuropathological findings with clinical presentation, including cognitive status.
Main Results:
- MSA-P cases demonstrated significantly higher alpha-synuclein pathology in the cortex and brainstem compared to MSA-C.
- Tau load was slightly higher in MSA-P with cognitive impairment, whereas Aβ load and CAA were more prominent in MSA-C.
- Lewy co-pathology was more frequent in MSA cases with cognitive decline but did not differ between MSA-P and MSA-C.
Conclusions:
- Neuropathological differences exist between MSA-P and MSA-C, particularly concerning tau and amyloid deposition.
- These findings align with clinical observations of more severe cognitive dysfunction in MSA-P.
- Further research is needed to fully understand the pathobiological basis of cognitive impairment in MSA phenotypes.
Related Concept Videos
Alzheimer's Disease: Overview
602
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
602
Dementia
153
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
153

